Aibin Liang

Tongji University — China

Medicine · Health Sciences

28h-index3.1kcitations232works3.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(84), Lymphoma Diagnosis and Treatment(33), Acute Myeloid Leukemia Research(32), Myeloproliferative Neoplasms: Diagnosis and Treatment(17), Virus-based gene therapy research(16)

Publications232 total

Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed/refractory acute myeloid leukemia
Journal of Hematology & Oncology·2025Open Access
Function‐driven design of a surrogate interleukin‐2 receptor ligand
FEBS Letters·2025Open Access
Benchmarking algorithms for generalizable single-cell perturbation response prediction
Nature Methods·2025· 1 cited
Targeting DESI2 as a Novel Therapeutic Strategy for JAK2‐Mutant Leukemias
Advanced Science·2025Open Access
Sequential PD-1 inhibitors as consolidative therapy post-CD19 CART in relapsed/refractory NHL: a propensity score matching cohort study
Journal of Translational Medicine·2025· 1 citedOpen Access
CARMA-1: The phase I Study of SENL101, a naturally selected nanobody based CD7 CAR-T therapy, in relapsed or refractory T-ALL/lbl
Blood·2025Open Access
Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with Philadelphia chromosome-positive b-ALL: Insights from real-world data
Blood·2025Open Access
Safety and efficacy of IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) in the treatment of primary/secondary central nervous system lymphoma
Blood·2025Open Access
Exploring molecular heterogeneity and clonal evolution in chronic myelomonocytic leukemia via single-cell transcriptome sequencing
Blood·2025Open Access
Real-world efficacy of inaticabtagene autoleucel in adult B-cell acute lymphoblastic leukemia patients with high-risk molecular alterations
Blood·2025
Characteristics and Outcomes of Second Primary Multiple Myeloma in Adult Cancer Survivors: A Population‐Based Cohort Study
Cancer Medicine·2025Open Access
A multicenter retrospective study of HDAC inhibitor- based regimen for relapsed/refractory non-hodgkin lymphoma patients post CAR-T therapy
Immunity & Inflammation·2025Open Access
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma
Experimental Hematology and Oncology·2025Open Access
Weakly supervised peptide-TCR binding prediction facilitates neoantigen identification
Cell Systems·2025
Combining CAR-T therapy with radiotherapy or not in refractory/relapsed diffuse large B-cell lymphoma: A comparative study
Clinical and Translational Radiation Oncology·2025Open Access
China Expert consensus on the application of metagenomic next-generation sequencing for the etiological diagnosis of infections in hematological disorders (2024)
Blood Science·2025· 1 citedOpen Access
A broadly neutralizing antibody recognizes a unique epitope with a signature motif common across coronaviruses
Nature Communications·2025· 6 citedOpen Access
Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults
Blood Advances·2025· 1 citedOpen Access
Germline mutations in B-cell non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH) and patient outcomes
Seminars in Oncology·2025· 1 cited
Phosphorylation‐Dependent Stabilization of Collaborator of ARF (CARF) Suppresses Lymphoma Cell Proliferation
Advanced Science·2025Open Access
page 1 of 12Next →

Frequent Co-authors

Wenjun Zhang(14), Ping Li(13), Wenbin Qian(11), Weidong Han(8), Jun Xu(8), Guangming Wang(7), Bing Xiu(6), Wen Lei(5), Shiguang Ye(5), Fangce Wang(5), Xi Zhang(4), Kailin Xu(4), Hui Liu(4), Jiong Hu(4), Fang Xia(4), Xianghua Yi(4), Junbang Wang(3), Yu Zeng(3), Ying Wang(3), Jiang Cao(3)